UDC

612.017+612.115.3

DOI

10.37482/2542-1298-Z010

Authors

Galina A. Sroslova*/** ORCID: 0000-0002-9118-7098
Mikhail S. Sroslov**** ORCID: 0000-0001-8565-5214
Andrey V. Strygin*/*** ORCID: 0000-0002-6997-1601
Mikhail V. Bukatin*** ORCID: 0000-0003-1031-0697
Boris E. Tolkachev*** ORCID: 0000-0002-7934-6586
Evgeniy I. Morkovin*/*** ORCID: 0000-0002-7119-3546
Natal’ya A. Kolobrodova*/*** ORCID: 0000-0002-8927-4811
Anna O. Strygina*/*** ORCID: 0000-0001-7478-2007
Ol’ga Yu. Kuznetsova*** ORCID: 0000-0002-9991-6136
Anna M. Dotsenko*/*** ORCID: 0000-0003-3324-3351
Oksana A. Lisina*** ORCID: 0000-0002-8017-4726
Liliya P. Knyshova*/*** ORCID: 0000-0001-6002-1231
Konstantin Yu. Tutaev* ORCID: 0000-0003-2678-2322
*Volgograd Medical Research Center (Volgograd, Russian Federation)
**Volgograd State University (Volgograd, Russian Federation)
***Volgograd State Medical University (Volgograd, Russian Federation)
****Research Institute of Hygiene, Toxicology and Occupational Pathology (Volgograd, Russian Federation)
Corresponding author: Natal’ya Kolobrodova, address: pl. Pavshikh bortsov 1, Volgograd, 400131, Russian Federation; e-mail: medbiochem@mail.ru

Abstract

Cytokines are low-molecular-weight polypeptides that can make a significant contribution to the regulation of haemostatic balance both in normal and pathological conditions. A particularly important role is played by the tissue factor (TF) as the initiator of coagulation. Moreover, it can participate in a number of other biological processes as a receptor. TF expression on monocytes is induced by the action of infectious agents, immune complexes, and pro-inflammatory cytokines; adhesion to other cells or to adhesive proteins is also relevant. The above factors can induce TF expression on endothelial cells as well, thereby not only increasing procoagulant activity, but also inhibiting the anticoagulant protein C pathway and affecting fibrinolysis. The specific modulatory effect on TF expression in the endothelium is exerted by advanced glycation end products, reactive oxygen species, and thrombin. The leading role of a number of cytokines in haemostatic disorders in patients with sepsis has been shown, as well as in pathophysiology of thrombotic complications in patients with antiphospholipid syndrome, hepatic veno-occlusive disease, autoimmune vasculitis, and cancer. With this in mind, several therapeutic approaches to reducing the production or activity of cytokines have been studied in experimental models of thrombosis, as well as in human trials. Examples of new antithrombotic agents are TF inhibitors, Fab fragments of monoclonal antibodies against factor VII or factor VIIa, and soluble tissue factor mutant. Another possible approach to antithrombotic therapy is the inhibition of cytokines involved in the regulation of TF expression using antibodies to tumour necrosis factor or interleukin-6. Thus, the fundamental discoveries describing the effect of cytokines on the coagulation system form the basis for the development of new therapeutic approaches to the correction of coagulation disorders.
For citation: Sroslova G.A., Sroslov M.S., Strygin A.V., Bukatin M.V., Tolkachev B.E., Morkovin E.I., Kolobrodova N.A., Strygina A.O., Kuznetsova O.Yu., Dotsenko A.M., Lisina O.A., Knyshova L.P., Tutaev K.Yu. Adaptation of Cell Elements Involved in Haemostasis Regulation to Cytokine Action (Review). Journal of Medical and Biological Research, 2020, vol. 8, no. 2, pp. 194–203. DOI: 10.37482/2542-1298-Z010

Keywords

pro-inflammatory cytokines, anti-inflammatory cytokines, tissue factor, leukocytes, immune response, tissue factor expression, coagulation, antithrombotic therapy

References

1. van Es N., Bleker S., Sturk A., Nieuwland R. Clinical Significance of Tissue Factor–Exposing Microparticles in Arterial and Venous Thrombosis. Semin. Thromb. Hemost., 2015, vol. 41, no. 7, pp. 718–727.
2. Gajsiewicz J.M., Morrissey J.H. Structure-Function Relationship of the Interaction Between Tissue Factor and Factor VIIa. Semin. Thromb. Hemost., 2015, vol. 41, no. 7, pp. 682–690.
3. Witkowski M., Landmesser U., Rauch U. Tissue Factor as a Link Between Inflammation and Coagulation. Trends Cardiovasc. Med., 2016, vol. 26, no. 4, pp. 297–303.
4. Madsen J.J., Persson E., Olsen O.H. Tissue Factor Activates Allosteric Networks in Factor VIIa Through Structural and Dynamic Changes. J. Thromb. Haemost., 2015, vol. 13, no. 2, pp. 262–267.
5. Hedner U. Recombinant Activated Factor VII: 30 Years of Research and Innovation. Blood Rev., 2015, vol. 29, suppl. 1, pp. S4–S8.
6. Rapaport S.I., Rao L.V. The Tissue Factor Pathway: How It Has Become a “Prima Ballerina”. Thromb. Haemost., 1995, vol. 74, no. 1, pp. 7–17.
7. Krudysz-Amblo J., Mann K.G., Butenas S. Tissue Factor Structure and Coagulation. Ercan E., Ece G. (eds.). Thrombosis and Inflammation in Acute Coronary Syndromes. Bentham Science Publishers, 2015, pp. 23–57.
8. Gimbrone M.A. Jr., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res., 2016, vol. 118, no. 4, pp. 620–636.
9. Tatsumi K., Mackman N. Tissue Factor and Atherothrombosis. J. Atheroscler. Thromb., 2015, vol. 22, no. 6, pp. 543–549.
10. Levi M., van der Poll T., Schultz M. Infection and Inflammation as Risk Factors for Thrombosis and Atherosclerosis. Semin. Thromb. Hemost., 2012, vol. 38, no. 5, pp. 506–514.
11. Hartman J., Frishman W.H. Inflammation and Atherosclerosis: A Review of the Role of Interleukin-6 in the Development of Atherosclerosis and the Potential for Targeted Drug Therapy. Cardiol. Rev., 2014, vol. 22, no. 3, pp. 147–151.
12. Hassan G.S., Merhi Y., Mourad W. CD40 Ligand: A Neo-Inflammatory Molecule in Vascular Diseases. Immunobiology, 2012, vol. 217, no. 5, pp. 521–532.
13. Xiao L., Liu Y., Wang N. New Paradigms in Inflammatory Signaling in Vascular Endothelial Cells. Am. J. Physiol. Heart Circ. Physiol., 2013, vol. 306, no. 3, pp. H317–H325.
14. Michaud M., Balardy L., Moulis G., Gaudin C., Peyrot C., Vellas B., Cesari M., Nourhashemi F. Proinflammatory Cytokines, Aging, and Age-Related Diseases. J. Am. Med. Dir. Assoc., 2013, vol. 14, no. 12, pp. 877–882.
15. Singh V.P., Bali A., Singh N., Jaggi A.S. Advanced Glycation End Products and Diabetic Complications. Korean J. Physiol. Pharmacol., 2014, vol. 18, no. 1, pp. 1–14.
16. Bodiga V.L., Eda S.R., Bodiga S. Advanced Glycation End Products: Role in Pathology of Diabetic Cardiomyopathy. Heart Fail. Rev., 2014, vol. 19, no. 1, pp. 49–63.
17. Luedde T., Kaplowitz N., Schwabe R.F. Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance. Gastroenterology, 2014, vol. 147, no. 4, pp. 765–783.e4.
18. DiDonato J.A., Mercurio F., Karin M. NF-κB and the Link Between Inflammation and Cancer. Immunol. Rev., 2012, vol. 246, no. 1, pp. 379–400.
19. Wada H., Matsumoto T., Yamashita Y. Diagnosis and Treatment of Disseminated Intravascular Coagulation (DIC) According to Four DIC Guidelines. J. Intensive Care, 2014, vol. 2. Art. no. 15.
20. Levi M., van der Poll T., Schultz M. New Insights into Pathways That Determine the Link Between Infection and Thrombosis. Neth. J. Med., 2012, vol. 70, no. 3, pp. 114–120.
21. Margetic S. Inflammation and Haemostasis. Biochem. Med. (Zagreb), 2012, vol. 22, no. 1, pp. 49–62.
22. Hunter C.A., Jones S.A. IL-6 as a Keystone Cytokine in Health and Disease. Nat. Immunol., 2015, vol. 16, no. 5, pp. 448–457.
23. Wang J.C., Bennett M. Aging and Atherosclerosis: Mechanisms, Functional Consequences, and Potential Therapeutics for Cellular Senescence. Circ. Res., 2012, vol. 111, no. 2, pp. 245–259.
24. Flammer A.J., Anderson T., Celermajer D.S., Creager M.A., Deanfield J., Ganz P., Hamburg N.M., Lüscher T.F., Shechter M., Taddei S., Vita J.A., Lerman A. The Assessment of Endothelial Function: From Research into Clinical Practice. Circulation, 2012, vol. 126, no. 6, pp. 753–767.
25. Aird W.C. Endothelial Cell Heterogeneity. Cold Spring Harb. Perspect. Med., 2012, vol. 2, no. 1. Art. no. a006429.
26. Falanga A., Russo L., Verzeroli C. Mechanisms of Thrombosis in Cancer. Thromb. Res., 2013, vol. 131, suppl. 1, pp. S59–S62.
27. Colombo R., Gallipoli P., Castelli R. Thrombosis and Hemostatic Abnormalities in Hematological Malignancies. Clin. Lymphoma Myeloma Leuk., 2014, vol. 14, no. 6, pp. 441–450.
28. Mitrugno A., Tormoen G.W., Kuhn P., McCarty O.J. The Prothrombotic Activity of Cancer Cells in the Circulation. Blood Rev., 2016, vol. 30, no. 1, pp. 11–19.
29. Colvin E.K. Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer. Front. Oncol., 2014, vol. 4. Art. no. 137.
30. Otsuka F., Finn A.V., Yazdani S.K., Nakano M., Kolodgie F.D., Virmani R. The Importance of the Endothelium in Atherothrombosis and Coronary Stenting. Nat. Rev. Cardiol., 2012, vol. 9, no. 8, pp. 439–453.
31. van der Poll T., Levi M. Crosstalk Between Inflammation and Coagulation: The Lessons of Sepsis. Curr. Vasc. Pharmacol., 2012, vol. 10, no. 5, pp. 632–638.
32. Williams J.C., Mackman N. Tissue Factor in Health and Disease. Front. Biosci. (Elite Ed.), 2012, vol. 4, pp. 358–372.
33. Demetz G., Ott I. The Interface Between Inflammation and Coagulation in Cardiovascular Disease. Int. J. Inflamm., 2012, vol. 2012. Art. no. 860301.
34. Simmons J., Pittet J.F. The Coagulopathy of Acute Sepsis. Curr. Opin. Anaesthesiol., 2015, vol. 28, no. 2, pp. 227–236.
35. van der Poll T., de Jonge E., ten Cate H. Cytokines as Regulators of Coagulation. Madame Curie Bioscience Database. Austin: Landes Bioscience, 2000–2013. Available at: https://www.ncbi.nlm.nih.gov/books/NBK6207/ (accessed: 14 April 2020).
36. Duburcq T., Tournoys A., Gnemmi V., Hubert T., Gmyr V., Pattou F., Jourdain M. Impact of Obesity on Endotoxin-Induced Disseminated Intravascular Coagulation. Shock, 2015, vol. 44, no. 4, pp. 341–347.